Synairgen plc
Price information
Instrument information
Last 5 trades
| Date | Time | Price | Currency | Volume | Trade Value | Trade type | Trade flag | MIC |
|---|---|---|---|---|---|---|---|---|
| 23.11.20 | 16:29:12 | 93.00 | GBX | 15,000 | 13,950.00 | Off-Book | LRGS | SINT |
| 23.11.20 | 16:23:04 | 92.60 | GBX | 20,000 | 18,520.00 | Off-Book | LRGS | AIMX |
| 23.11.20 | 16:21:32 | 93.40 | GBX | 21,399 | 19,986.45 | Off-Book | LRGS | AIMX |
| 23.11.20 | 16:14:12 | 92.60 | GBX | 15,000 | 13,890.00 | Off-Book | LRGS | AIMX |
| 23.11.20 | 16:08:01 | 93.00 | GBX | 15,000 | 13,949.25 | Off-Book | LRGS | AIMX |
Equity Research
from Synairgen plc
Rude Health - finnCap Life Sciences quarterly sector note
Oxford University and AstraZeneca announced the first interim analysis from the Phase III study of its COVID-19 vaccine candidate, which was found to be 70% effective in preventing COVID-19. This follows similar announcements from Moderna, and Pfizer/BioNTech in the previous two weeks, and the cavea ...
View report
Synairgen - £80m funding for COVID-19 study and supply chain
Synairgen has raised £80m to fund a Phase III trial for SNG001 in COVID-19 disease, which is due to commence in Q4 2020 and will be run globally by Parexel, with results expected in Q2 2021, and scale up manufacturing. This follows a successful pre-IND meeting with the FDA, which provided the guidan ...
View reportMorning Note – 29 September 2020
Chariot Oil & Gas (CHAR): Corp | dotDigital (DOTD): Corp | Gateley (GTLY): Corp | Iofina (IOF): Corp | Synairgen (SNG): Corp | Universe Group (UNG): Corp
View report
Synairgen - Interims and fuller Phase II data analysis
Synairgen reported interim results to 30 June in which the adjusted net loss was £3.9m with period-end cash of £10.9m. A fuller analysis and disclosure of the Phase II trial of inhaled interferon (SNG001) in hospitalised COVID-19 patients confirms the earlier optimism we had at the ti ...
View reportSP Angel Healthcare Conditions
Synairgen (SNG.L): Positive interim data from trial of SNG001 in COPD patients | Silence Therapeutics (SLN.L): R&D Update | Verona Pharma plc (AIM: VRP.L): Initation of pilot study in COVID-19 patients
View report